RLMD
Relmada Therapeutics, Inc.
1W: +7.2%
1M: +56.3%
3M: +48.3%
YTD: +52.4%
1Y: +2105.3%
3Y: +1000.8%
5Y: -6.2%
$6.66
+0.56 (+9.18%)
After Hours: $6.60 (-0.06, -0.90%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$19.3M
Congress—
ETF Holdings—
Key Statistics
Market Cap$488.4M
52W Range0.243-7.51
Volume1,650,867
Avg Volume1,463,583
Beta0.73
Dividend—
Analyst Ratings
Company Info
CEOSergio Traversa
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-20
Websiterelmada.com
2222 Ponce de Leon Boulevard
Coral Gables, FL 33134
US
Coral Gables, FL 33134
US
786 629 1376
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Latest News
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest
Relmada wins bullish view at Piper Sandler on cancer therapy
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives $9.00 Consensus Target Price from Analysts
Relmada (RLMD) Q4 2025 Earnings Call Transcript
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| TRAVERSA SERGIO | P-Purchase | 27,500 | $4.12 | 2025-12-15 |
| Shenouda Maged | P-Purchase | 11,665 | $4.12 | 2025-12-15 |
| TRAVERSA SERGIO | A-Award | 1,198,000 | $4.06 | 2025-12-12 |
| Shenouda Maged | A-Award | 828,000 | $4.06 | 2025-12-12 |
| Ence Chuck | A-Award | 828,000 | $4.06 | 2025-12-12 |